Journal
CLINICAL CANCER RESEARCH
Volume 26, Issue 17, Pages 4551-4558Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-20-0587
Keywords
-
Categories
Funding
- National Nature Science Foundation of China [81972375]
- Shanghai Rising Star Program [16QA1401100]
- Fudan University Shanghai Cancer Center Fund [YJJQ201802, YJQN201923]
- Shanghai Rising Stars of Medical Talent Youth Development Program [2018ZY]
Ask authors/readers for more resources
Purpose: Tumor heterogeneity and burden, which impact treatment outcome in prostate cancer, are rarely evaluated using next-generation imaging. Experimental Design: The trial prospectively included 37 patients who had an early PSA progression (<= 2 ng/mL) during castration and high-risk (PSA doubling time <= 10 months) non-metastatic disease by conventional imaging. All patients underwent both Ga-68-PSMA and F-18-FDG PET/CT. Lesions were classified into PSMA+FDG +/- lesions and PSMA-FDG+lesions. The primary endpoint was the prevalence of PSMA-FDG+ disease. Tumor burden, predictors for positive imaging, and suitability for oligo-metastases-directed therapy (OMDT) were also evaluated. Results: All patients were treated with RP and the median duration of castration was 23 months. The median PSA at imaging was 0.57 ng/mL. Overall, 114 lesions were detected in 29 of the 37 patients. A high prevalence (73%) of N+/M+disease was observed. Of the 114 lesions, 81 were PSMA+FDG +/- and 33 were PSMA-FDG+. Per patient level, 9 men (24%; 95% confidence interval: 10%-39%) showed at least one new PSMA-FDG+ lesions. A short PSA doubling time (P = 0.009, OR = 8.000) was associated with PSMA+FDG +/- disease, while a high Gleason grade group (P = 0.022, OR = 13.091) with PSMA-FDG+ disease. Nineteen patients (51%) with 51 lesions, including 10 PSMA-FDG+ lesions, could be enrolled for OMDT. Among different disease stages, PSMA-FDG+ disease was rarely detected in the hormone-sensitive cohort, but frequently found in the castration-resistant cohort. Conclusions: Using Ga-68-PSMA and F-18-FDG PET, we observed a high prevalence of N+/M+disease and a significant proportion of PSMA-FDG+ disease in patients with an early PSA progression during castration (ChiCTR1900022634).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available